<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39316386</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2105</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Journal of the National Cancer Institute</Title><ISOAbbreviation>J Natl Cancer Inst</ISOAbbreviation></Journal><ArticleTitle>Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 decline.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">djae180</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/jnci/djae180</ELocationID><Abstract><AbstractText>The COVID-19 pandemic led to substantial declines in cancer incidence rates in 2020, likely because of disruptions in screening and diagnostic services. This study aimed to assess the impact of the pandemic on cancer incidence rates in the United States using 2021 incidence data from the Surveillance, Epidemiology, and End Results program. The analysis compared observed 2021 cancer incidence rates with expected prepandemic trends, evaluating changes by individual cancer site and stage. Although incidence overall and in many cancer sites the rates were close to prepandemic levels, they did not exhibit a recovery that incorporated the delayed diagnoses from 2020. There were exceptions, however, such as metastatic breast cancer, which showed significantly higher observed rates than expected (rate ratio = 1.09, 95% confidence interval = 1.04 to 1.13). Ongoing monitoring and targeted interventions are needed to address the long-term consequences of the COVID-19 pandemic on cancer care and outcomes.</AbstractText><CopyrightInformation>Published by Oxford University Press 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Howlader</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1989-1478</Identifier><AffiliationInfo><Affiliation>Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Huann-Sheng</ForeName><Initials>HS</Initials><Identifier Source="ORCID">0000-0002-5905-8050</Identifier><AffiliationInfo><Affiliation>Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noone</LastName><ForeName>Anne-Michelle</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Information Management Services, Calverton, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Jeffry</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Information Management Services, Calverton, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Negoita</LastName><ForeName>Serban</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9327-9519</Identifier><AffiliationInfo><Affiliation>Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cronin</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariotto</LastName><ForeName>Angela B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Surveillance Research Program</Agency><Country /></Grant><Grant><Agency>Division of Cancer Control and Population Sciences</Agency><Country /></Grant><Grant><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Natl Cancer Inst</MedlineTA><NlmUniqueID>7503089</NlmUniqueID><ISSNLinking>0027-8874</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39316386</ArticleId><ArticleId IdType="doi">10.1093/jnci/djae180</ArticleId><ArticleId IdType="pii">7765196</ArticleId></ArticleIdList></PubmedData></PubmedArticle>